HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ceralifimod

a sphingosine 1-phosphate receptor modulator; structure in first source

Also Known As:

ONO-4641

Networked: 6 relevant articles (2 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azetines
    - Azetidines: 6
      - ceralifimod: 6
Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Naphthalenes: 18
        ceralifimod: 6
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Naphthalenes: 18
    - ceralifimod: 6

Experts

1.	Komiya, Takaki: 2 articles (01/2021 - 11/2018)
2.	Shioya, Hiroki: 2 articles (01/2021 - 01/2021)
3.	Gohda, Masashi: 1 article (01/2021)
4.	Habashita, Hiromu: 1 article (01/2021)
5.	Hiraizumi, Kenji: 1 article (01/2021)
6.	Hoshino, Tomohiro: 1 article (01/2021)
7.	Inagaki, Yuichi: 1 article (01/2021)
8.	Katsumata, Seishi: 1 article (01/2021)
9.	Kurata, Haruto: 1 article (01/2021)
10.	Nakade, Shinji: 1 article (01/2021)

Related Diseases

1.	Aplastic Anemia (Anemia, Hypoplastic) 01/01/2021 - "We evaluated the efficacy of ONO-4641 in a mouse model of aplastic anemia. " 01/01/2021 - "These observations indicate, for the first time, that S1P receptor modulators demonstrate efficacy in the mouse model of aplastic anemia and suggest that treatment with ONO-4641 might delay the progression of aplastic anemia. " 01/01/2021 - "Sphingosine 1-Phosphate Receptor Modulator ONO-4641 Regulates Trafficking of T Lymphocytes and Hematopoietic Stem Cells and Alleviates Immune-Mediated Aplastic Anemia in a Mouse Model." 01/01/2021 - "SIGNIFICANCE STATEMENT: ONO-4641 is a second-generation sphingosine 1-phosphate (S1P) receptor modulator selective for S1P receptors 1 and 5. In this study, we demonstrated that ONO-4641 regulates the trafficking of T lymphocytes along with hematopoietic stem and progenitor cells, leading to alleviation of pancytopenia and destruction of bone marrow in a bone marrow failure-induced mouse model mimicking human aplastic anemia."
2.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/01/2021 - "These observations suggest ONO-4641 may delay the onset and progression of type 1 diabetes mellitus." 01/01/2021 - "ONO-4641 was tested in non-obese diabetic (NOD) mice, an animal model of spontaneous type 1 diabetes mellitus, an autoimmune disease with unmet medical needs. " 01/01/2021 - "Preventive and Therapeutic Efficacy of ONO-4641, a Selective Agonist for Sphingosine 1-Phosphate Receptor 1 and 5, in Preclinical Models of Type 1 Diabetes Mellitus."
3.	Lymphopenia (Lymphocytopenia) 11/01/2018 - "Lymphocytopenia observed in these models likely contributed to beneficial ONO-4641 effects. " 11/01/2018 - "Thus, ONO-4641 attenuated murine pulmonary emphysema by expanding lung CD11b+Gr-1+ cell populations and inducing lymphocytopenia. " 11/01/2018 - "In this study, we demonstrated that the S1P receptor modulator ONO-4641 induced the expansion of lung CD11b+Gr-1+ cells and lymphocytopenia in naive mice. " 09/01/2015 - "Safety biomarker results suggest that potential therapeutic doses of ceralifimod, in particular the 0.05-mg dose, might result in reduced occurrence of bradycardia, atrioventricular block absolute lymphocyte count and grade 3/4 lymphopenia compared with fingolimod 0.5 mg. "
4.	Autoimmune Diseases (Autoimmune Disease) 01/01/2021 - "ONO-4641 was tested in non-obese diabetic (NOD) mice, an animal model of spontaneous type 1 diabetes mellitus, an autoimmune disease with unmet medical needs. " 01/01/2014 - "Proof-of-concept studies across validated animal models with S1P receptor modulators highly selective for S1P1, such as BAF-312 (Siponimod), KRP-203, ONO-4641 (Ceralifimod), ponesimod and RPC-1063, and emerging clinical trials for safety and efficacy in humans, particularly in MS, ulcerative colitis (UC) and psoriasis, have set the stage for us to consider additional testing in various other autoimmune diseases. "
5.	Psoriasis (Pustulosis Palmaris et Plantaris) 01/01/2014 - "Proof-of-concept studies across validated animal models with S1P receptor modulators highly selective for S1P1, such as BAF-312 (Siponimod), KRP-203, ONO-4641 (Ceralifimod), ponesimod and RPC-1063, and emerging clinical trials for safety and efficacy in humans, particularly in MS, ulcerative colitis (UC) and psoriasis, have set the stage for us to consider additional testing in various other autoimmune diseases. "

Related Drugs and Biologics

1.	Sphingosine-1-Phosphate Receptors
2.	ceralifimod
3.	sphingosine 1-phosphate (sphingosine-1-phosphate)
4.	siponimod
5.	ponesimod
6.	KRP-203
7.	Biomarkers (Surrogate Marker)
8.	Smoke
9.	Pancreatic Elastase (Elastase)
10.	Azetidinecarboxylic Acid